2021/12/4  
Taiwan in talks to buy Merck’s COVID-19 pill (2021/10/05)
其它新聞 Other News   
  • White House ‘concerned’ over spike in Chinese aircraft incursions
  • Taiwan heroes to lead anthem on National Day
  • New Zealand approves Taiwan-made Medigen vaccine for entry from Nov. 1
  • Nearly 100% of long-haul air crew fully vaccinated
  • Eric Chu assumes post as KMT chairman
  • Auto industry giant announces price rises, as silicon chips remain in short supply
  • Wooden products shine at Forestry Bureau Taiwanese Material Design Contest
  • TRA gives internships to high-schoolers from St. Joseph Technical High School
  • Nantou snack van owner offers free meals to kids struggling with their studies
  • Storms brewing but clouds to part on National Day
  • 英文 English 
    Taiwan in talks to buy Merck’s COVID-19 pill (2021/10/05)

    Molnupiravir is a pill that could cut the risk of COVID death by about half. That’s according to interim testing data released by the drug’s American developers. The treatment is not yet approved for use in the U.S., but there’s already a global rush to place orders. Taiwan is in talks over a purchasing agreement, to lock in a supply of this promising pill.

    U.S. pharma firms Merck and Ridgeback Biotherapeutics have released interim trial data on their oral drug for COVID, molnupiravir. The findings suggest the drug can reduce the risk of death and hospitalization by 50%. But a Taiwan doctor warns that the pill is not a panacea.

    Lee Ping-ing
    CECC Specialist Advisory Panel
    If you have breathing difficulties and your oxygen levels are dropping, oral drugs may not be the way to go. Injections may have a better effect. Right now we don’t yet know whether there are any differences between oral and injectable treatments. In any case, injections are more reliable in terms of absorption. They aren’t affected by the absorption rate of the stomach and intestines.

    The digestive system’s absorption rate can affect the effectiveness of oral-use drugs. The CECC is currently in talks to procure the drug, which is a pill that’s taken at home to reduce the risk of hospitalization.

    Currently Taiwan administers Remdesivir to patients receiving oxygen support in the hospital. Monoclonal antibodies are given to at-risk patients with mild or moderate symptoms. The new pill would be prescribed to high-risk patients with recent infections.

    Health experts say that once a patient develops severe symptoms, it’s usually too late to administer any drug.

    Lee Ping-ing
    CECC Specialist Advisory Panel
    The thing about these three drugs is that, if you take them after you develop severe symptoms and become hospitalized, their effects may not be as pronounced. Or they may have no effect at all. These drugs need to be taken when symptoms are mild, right when the virus starts reproducing. That’s when you can inhibit it. That’s when the drug will have an effect.

    The CECC adviser says that any of these three drugs, if administered early, can reduce the risk of severe illness and death by 60% to 70%. With the epidemic contained, the CECC is securing the supplies required to fight another outbreak.
    中文 Chinese  
    默沙東口服藥 李秉穎:腸胃吸收力影響藥效

    默沙東的武肺口服新藥準備提出EUA,引起全球關注,,指揮中心也正洽談購買,並預告以後染疫可能在家服藥不用到醫院打針,更有人期待今後是不是就不用戴口罩了,但醫師李秉穎強調,口服藥固然方便,但瑞德西韋等針劑也很重要,因為不會受到腸胃吸收比例的影響。

    美國藥廠默沙東宣布研發出口服新藥,臨床試驗數據顯示,可將重症患者的死亡或住院機率減半,搶救更多人命,但醫師認為不必神話口服藥物。

    [[指揮中心專家諮詢小組委員 李秉穎]]
    “如果你是有呼吸困難,氧氣下降的情形的話,就比較不需要去用口服的藥,說不定用注射的藥物會比較好,我們現在是不知道說,口服的藥跟注射的藥,有沒有什麼不一樣,不過注射的針劑畢竟,它的吸收是比較可靠,它不會受到腸胃吸收比例的影響”

    腸胃吸收能力好不好會影響口服藥效,但這款口服藥物正由指揮中心洽購中,並預告未來染疫,可能就不用到醫院打針,而是在家吃藥。

    現行藥物包括瑞德西韋,台灣主要用在住院須用氧氣的患者,單株抗體藥物則用在輕、中度感染高風險患者,默沙東新藥規劃用在染疫初期的高風險患者。

    但醫師警告,武肺病毒狡猾,演變成重症,恐怕連藥物都派不上用場。

    [[指揮中心專家諮詢小組委員 李秉穎]]
    “這三種藥物的特點都是,你如果變成重症,住院以後它的效果就可能不顯著,或甚至完全沒有效果,你必須在輕症的時候,在病毒剛開始要繁殖的時候,就把它抑制下來才會有用”

    李秉穎指出,三款藥物都建議用在患病初期,防重症跟防死亡都能來到六到七成,疫情趨緩時政府做好戰備,避免疫情爆發時無藥可用,但防疫關鍵還是在全民自己。
    關於民視 常見問題 如何收看民視 意見信箱

    © 2009 FTV All Rights Reserved 版權所有‧盜用必究 Designed by FTV
    地址:244 新北市林口區信義路99號   觀服電話:(02)8601-8601 服務時間:週一至週日09:00-21:00   傳真:(02)8601-3955

    本網站使用 cookie 與其他技術為您提供更好的使用體驗, 請閱讀我們的的隱私權政策,通過使用我們的網站,表示您確認並同意我們的政策。